156 related articles for article (PubMed ID: 25100024)
21. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L; Carrupt PA; Abriel H; Daina A
Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
[TBL] [Abstract][Full Text] [Related]
22. Development and evaluation of an in silico model for hERG binding.
Song M; Clark M
J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
[TBL] [Abstract][Full Text] [Related]
23. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
24. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
25. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations.
Recanatini M; Cavalli A; Masetti M
ChemMedChem; 2008 Apr; 3(4):523-35. PubMed ID: 18224703
[TBL] [Abstract][Full Text] [Related]
26. Probing the molecular basis of hERG drug block with unnatural amino acids.
Macdonald LC; Kim RY; Kurata HT; Fedida D
Sci Rep; 2018 Jan; 8(1):289. PubMed ID: 29321549
[TBL] [Abstract][Full Text] [Related]
27. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
28. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
29. The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel.
Guo J; Han SN; Liu JX; Zhang XM; Hu ZS; Shi J; Zhang LR; Zhao ZZ; Zhang Z
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):643-9. PubMed ID: 20662825
[TBL] [Abstract][Full Text] [Related]
30. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Imai YN; Ryu S; Oiki S
J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
[TBL] [Abstract][Full Text] [Related]
31. Revealing Molecular Determinants of hERG Blocker and Activator Binding.
Dickson CJ; Velez-Vega C; Duca JS
J Chem Inf Model; 2020 Jan; 60(1):192-203. PubMed ID: 31880933
[TBL] [Abstract][Full Text] [Related]
32. Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.
Choi SH; Shin TJ; Hwang SH; Lee BH; Kang J; Kim HJ; Jo SH; Choe H; Nah SY
Eur J Pharmacol; 2011 Aug; 663(1-3):59-67. PubMed ID: 21586280
[TBL] [Abstract][Full Text] [Related]
33. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
34. Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K
Ma S; Sun Z; Jing Y; McGann M; Vajda S; Enyedy IJ
Chem Res Toxicol; 2022 Aug; 35(8):1359-1369. PubMed ID: 35895844
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity.
Koulgi S; Jani V; Nair V; Saini JS; Phukan S; Sonavane U; Joshi R; Kamboj R; Palle V
J Biomol Struct Dyn; 2022 Aug; 40(13):5996-6012. PubMed ID: 33494645
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
37. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
38. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Deng Q; Lim YH; Anand R; Yu Y; Kim JH; Zhou W; Zheng J; Tempest P; Levorse D; Zhang X; Greene S; Mullins D; Culberson C; Sherborne B; Parker EM; Stamford A; Ali A
Bioorg Med Chem Lett; 2015 Aug; 25(15):2958-62. PubMed ID: 26048804
[TBL] [Abstract][Full Text] [Related]
39. Development of Safe Drugs: The hERG Challenge.
Kalyaanamoorthy S; Barakat KH
Med Res Rev; 2018 Mar; 38(2):525-555. PubMed ID: 28467598
[TBL] [Abstract][Full Text] [Related]
40. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
